ENB:TSXEnbridge Inc. Analysis
Data as of 2026-03-09 - not real-time
CA$73.30
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Enbridge (ENB.TO) is trading at C$73.3, comfortably above its 20‑day (C$71.7), 50‑day (C$68.0) and 200‑day (C$65.9) simple moving averages, confirming a bullish technical backdrop. The RSI of 64.9 and a bullish MACD histogram (+0.02) reinforce momentum, while the price sits near the identified resistance of C$74.39. Fundamentally, the stock offers a 5.28% dividend yield but the payout ratio exceeds 100% (1.17), raising questions about sustainability despite recent dividend hikes. Revenue growth of 5.9% and operating margins near 18% support cash‑flow generation, yet free cash flow is slightly negative and the debt‑to‑equity ratio is high at 161%, indicating leverage risk. Analyst consensus remains a “buy” with a median target of C$75, implying modest upside (~1.6%) and the DCF model aligns closely with the current price.
The latest news highlights a raised quarterly dividend and a major pipeline expansion, both of which have amplified investor optimism, reflected in an “Extreme Greed” market sentiment (75.9). However, decreasing volume, regulatory scrutiny of pipeline projects, and the elevated payout ratio suggest caution. Overall, ENB presents a blend of income appeal and moderate growth, but investors should monitor earnings coverage and leverage before committing.
The latest news highlights a raised quarterly dividend and a major pipeline expansion, both of which have amplified investor optimism, reflected in an “Extreme Greed” market sentiment (75.9). However, decreasing volume, regulatory scrutiny of pipeline projects, and the elevated payout ratio suggest caution. Overall, ENB presents a blend of income appeal and moderate growth, but investors should monitor earnings coverage and leverage before committing.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with bullish technicals
- Upcoming Q4 earnings focus on dividend coverage
- Decreasing volume indicating potential short‑term consolidation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst median target above current price
- Pipeline expansion expected to boost cash flow
- Attractive dividend yield despite payout concerns
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Stable regulated cash‑flow business model
- High leverage and regulatory exposure
- Dividend sustainability risk from >100% payout ratio
Key Metrics & Analysis
Financial Health
Revenue Growth5.90%
Profit Margin11.49%
P/E Ratio22.8
ROE11.56%
ROA3.38%
Debt/Equity161.40
P/B Ratio2.9
Op. Cash FlowCA$12.3B
Free Cash FlowCA$-239250000
Industry P/E20.6
Technical Analysis
TrendBullish
RSI64.9
SupportCA$67.93
ResistanceCA$74.39
MA 20CA$71.72
MA 50CA$67.99
MA 200CA$65.89
MACDBullish
VolumeDecreasing
Fear & Greed Index75.89
Valuation
Fair ValueCA$21.93
Target PriceCA$74.48
Upside/Downside1.60%
GradeFair
TypeBlend
Dividend Yield5.28%
Risk Assessment
Beta0.08
Volatility21.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.